Stay updated on Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The clinical trial record is displayed in place of a 403 Forbidden error, including the study overview, eligibility criteria, treatment arms, and outcome measures.
    Difference
    70%
    Check dated 2026-11-10T00:20:35.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T00:05:42.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    A sitewide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-27T00:15:45.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-20T00:54:10.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 on the ClinicalTrials.gov 403 error page.
    Difference
    0.2%
    Check dated 2026-10-13T06:17:35.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with basic site chrome, replacing the previous study details; the detailed study content and documents have been removed, leaving an error page.
    Difference
    22%
    Check dated 2026-09-22T00:23:42.000Z thumbnail image

Stay in the know with updates to Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.